Baidu
map

Obstet Gynecol:子痫前期孕妇更容易发生视网膜疾病

2016-12-08 haofan MedSci原创

子痫前期,特别严重的或是早发型子痫前期、妊娠后几十年母亲视网膜疾病发生高风险相关。

最近,妇产科领域权威杂志Obstetrics and Gynecology上发表了一篇研究文章,旨在评估子痫前期是否与妊娠后数十年母亲视网膜疾病的发生风险存在相关性。

研究人员进行了一项纵向队列研究,于1989年至2013年期间在加拿大魁北克省各个医院进行分娩的1,108,541名妇女纳入研究。研究人员调查追踪了作为研究对象的妇女之后的住院情况,随访时间截止到2014年3月31日。在分娩时对子痫前期进行测量,并根据严重程度(轻度或重度)和发病时间(之前或34周或34周以上的妊娠)进行分类。

主要终点事件为住院治疗和因视网膜脱离、视网膜病变或其他视网膜疾病而住院治疗。研究人员采用Cox回归模型估计子痫前期孕妇与无子痫前期孕妇比较而得的危险比和95%可信区间,并对糖尿病和高血压等因素进行了调整。

与无子痫前期孕妇相比,有子痫前期的妇女几十年后有较高的因视网膜脱离(52.9 vs. 23.9/10000人)、视网膜病变(60.5 vs. 8.0/10000人)和其他视网膜疾病(13.3 vs. 7.3/10000人)而住院治疗的发生率。


子痫前期与视网膜牵引脱离(风险比为2.39,95%可信区间为1.52-3.74)、视网膜裂孔(风险比为2.48,95%可信区间为1.40-4.41),以及糖尿病视网膜病变(风险比为4.13,95%可信区间为3.39-5.04)密切相关。与轻度或晚发型子痫前期相比,重度早发型子痫前期和有更高的视网膜疾病发生风险相关。

由此可见,子痫前期,特别严重的或是早发型子痫前期,妊娠后几十年母亲视网膜疾病发生高风险相关。

原始出处:

Auger, Nathalie, et al. Preeclampsia and Long-term Risk of Maternal Retinal Disorders. obstetrics and gynecology. December 02, 2016.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1648510, encodeId=728e164851098, content=<a href='/topic/show?id=57ff90e801c' target=_blank style='color:#2F92EE;'>#视网膜疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90780, encryptionId=57ff90e801c, topicName=视网膜疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f87823597669, createdName=xuyong531, createdTime=Fri Dec 16 02:18:00 CST 2016, time=2016-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011270, encodeId=156e20112e006, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Sun May 21 22:18:00 CST 2017, time=2017-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043934, encodeId=0fa72043934c4, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Mar 08 05:18:00 CST 2017, time=2017-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269842, encodeId=d4f412698427e, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sat Dec 10 12:18:00 CST 2016, time=2016-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366549, encodeId=d7321366549bf, content=<a href='/topic/show?id=097a452219b' target=_blank style='color:#2F92EE;'>#子痫前期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45221, encryptionId=097a452219b, topicName=子痫前期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Sat Dec 10 12:18:00 CST 2016, time=2016-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=161381, encodeId=7eed161381ba, content=学习了,继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo5nmIH5IQqCKjJgSCuicPWUWOUcdqt1ROPnEiaOYN4pSHibDv8la3OxNLalvuvUXn8clpJlrpuyTpckgt9OPkeSSdT/0, createdBy=8fd71930726, createdName=半夏微凉, createdTime=Fri Dec 09 09:09:15 CST 2016, time=2016-12-09, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1648510, encodeId=728e164851098, content=<a href='/topic/show?id=57ff90e801c' target=_blank style='color:#2F92EE;'>#视网膜疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90780, encryptionId=57ff90e801c, topicName=视网膜疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f87823597669, createdName=xuyong531, createdTime=Fri Dec 16 02:18:00 CST 2016, time=2016-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011270, encodeId=156e20112e006, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Sun May 21 22:18:00 CST 2017, time=2017-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043934, encodeId=0fa72043934c4, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Mar 08 05:18:00 CST 2017, time=2017-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269842, encodeId=d4f412698427e, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sat Dec 10 12:18:00 CST 2016, time=2016-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366549, encodeId=d7321366549bf, content=<a href='/topic/show?id=097a452219b' target=_blank style='color:#2F92EE;'>#子痫前期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45221, encryptionId=097a452219b, topicName=子痫前期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Sat Dec 10 12:18:00 CST 2016, time=2016-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=161381, encodeId=7eed161381ba, content=学习了,继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo5nmIH5IQqCKjJgSCuicPWUWOUcdqt1ROPnEiaOYN4pSHibDv8la3OxNLalvuvUXn8clpJlrpuyTpckgt9OPkeSSdT/0, createdBy=8fd71930726, createdName=半夏微凉, createdTime=Fri Dec 09 09:09:15 CST 2016, time=2016-12-09, status=1, ipAttribution=)]
    2017-05-21 yhy100200
  3. [GetPortalCommentsPageByObjectIdResponse(id=1648510, encodeId=728e164851098, content=<a href='/topic/show?id=57ff90e801c' target=_blank style='color:#2F92EE;'>#视网膜疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90780, encryptionId=57ff90e801c, topicName=视网膜疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f87823597669, createdName=xuyong531, createdTime=Fri Dec 16 02:18:00 CST 2016, time=2016-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011270, encodeId=156e20112e006, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Sun May 21 22:18:00 CST 2017, time=2017-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043934, encodeId=0fa72043934c4, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Mar 08 05:18:00 CST 2017, time=2017-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269842, encodeId=d4f412698427e, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sat Dec 10 12:18:00 CST 2016, time=2016-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366549, encodeId=d7321366549bf, content=<a href='/topic/show?id=097a452219b' target=_blank style='color:#2F92EE;'>#子痫前期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45221, encryptionId=097a452219b, topicName=子痫前期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Sat Dec 10 12:18:00 CST 2016, time=2016-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=161381, encodeId=7eed161381ba, content=学习了,继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo5nmIH5IQqCKjJgSCuicPWUWOUcdqt1ROPnEiaOYN4pSHibDv8la3OxNLalvuvUXn8clpJlrpuyTpckgt9OPkeSSdT/0, createdBy=8fd71930726, createdName=半夏微凉, createdTime=Fri Dec 09 09:09:15 CST 2016, time=2016-12-09, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1648510, encodeId=728e164851098, content=<a href='/topic/show?id=57ff90e801c' target=_blank style='color:#2F92EE;'>#视网膜疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90780, encryptionId=57ff90e801c, topicName=视网膜疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f87823597669, createdName=xuyong531, createdTime=Fri Dec 16 02:18:00 CST 2016, time=2016-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011270, encodeId=156e20112e006, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Sun May 21 22:18:00 CST 2017, time=2017-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043934, encodeId=0fa72043934c4, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Mar 08 05:18:00 CST 2017, time=2017-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269842, encodeId=d4f412698427e, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sat Dec 10 12:18:00 CST 2016, time=2016-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366549, encodeId=d7321366549bf, content=<a href='/topic/show?id=097a452219b' target=_blank style='color:#2F92EE;'>#子痫前期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45221, encryptionId=097a452219b, topicName=子痫前期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Sat Dec 10 12:18:00 CST 2016, time=2016-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=161381, encodeId=7eed161381ba, content=学习了,继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo5nmIH5IQqCKjJgSCuicPWUWOUcdqt1ROPnEiaOYN4pSHibDv8la3OxNLalvuvUXn8clpJlrpuyTpckgt9OPkeSSdT/0, createdBy=8fd71930726, createdName=半夏微凉, createdTime=Fri Dec 09 09:09:15 CST 2016, time=2016-12-09, status=1, ipAttribution=)]
    2016-12-10 zutt
  5. [GetPortalCommentsPageByObjectIdResponse(id=1648510, encodeId=728e164851098, content=<a href='/topic/show?id=57ff90e801c' target=_blank style='color:#2F92EE;'>#视网膜疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90780, encryptionId=57ff90e801c, topicName=视网膜疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f87823597669, createdName=xuyong531, createdTime=Fri Dec 16 02:18:00 CST 2016, time=2016-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011270, encodeId=156e20112e006, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Sun May 21 22:18:00 CST 2017, time=2017-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043934, encodeId=0fa72043934c4, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Mar 08 05:18:00 CST 2017, time=2017-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269842, encodeId=d4f412698427e, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sat Dec 10 12:18:00 CST 2016, time=2016-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366549, encodeId=d7321366549bf, content=<a href='/topic/show?id=097a452219b' target=_blank style='color:#2F92EE;'>#子痫前期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45221, encryptionId=097a452219b, topicName=子痫前期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Sat Dec 10 12:18:00 CST 2016, time=2016-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=161381, encodeId=7eed161381ba, content=学习了,继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo5nmIH5IQqCKjJgSCuicPWUWOUcdqt1ROPnEiaOYN4pSHibDv8la3OxNLalvuvUXn8clpJlrpuyTpckgt9OPkeSSdT/0, createdBy=8fd71930726, createdName=半夏微凉, createdTime=Fri Dec 09 09:09:15 CST 2016, time=2016-12-09, status=1, ipAttribution=)]
    2016-12-10 yahu
  6. [GetPortalCommentsPageByObjectIdResponse(id=1648510, encodeId=728e164851098, content=<a href='/topic/show?id=57ff90e801c' target=_blank style='color:#2F92EE;'>#视网膜疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90780, encryptionId=57ff90e801c, topicName=视网膜疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f87823597669, createdName=xuyong531, createdTime=Fri Dec 16 02:18:00 CST 2016, time=2016-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011270, encodeId=156e20112e006, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Sun May 21 22:18:00 CST 2017, time=2017-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043934, encodeId=0fa72043934c4, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Mar 08 05:18:00 CST 2017, time=2017-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269842, encodeId=d4f412698427e, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sat Dec 10 12:18:00 CST 2016, time=2016-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366549, encodeId=d7321366549bf, content=<a href='/topic/show?id=097a452219b' target=_blank style='color:#2F92EE;'>#子痫前期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45221, encryptionId=097a452219b, topicName=子痫前期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Sat Dec 10 12:18:00 CST 2016, time=2016-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=161381, encodeId=7eed161381ba, content=学习了,继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo5nmIH5IQqCKjJgSCuicPWUWOUcdqt1ROPnEiaOYN4pSHibDv8la3OxNLalvuvUXn8clpJlrpuyTpckgt9OPkeSSdT/0, createdBy=8fd71930726, createdName=半夏微凉, createdTime=Fri Dec 09 09:09:15 CST 2016, time=2016-12-09, status=1, ipAttribution=)]
    2016-12-09 半夏微凉

    学习了,继续关注!

    0

相关资讯

Diabet Med:无论有没有GDM,超重/肥胖都会增加剖宫产、子痫前期和大于胎龄儿的风险

肥胖的妊娠期糖尿病孕妇与正常体重高的非妊娠糖尿病孕妇相比,剖宫产、先兆子痫和大于胎龄儿的风险更大,不过近期的研究也表明,不管孕妇有没有妊娠糖尿病,超重和肥胖增加以上提到的风险。瑞典Örebro大学医学与健康科学学院的Karin Hilden博士和同事分析了1249908例孕妇BMI至少18.5 kg/m²的单胎妊娠情况,1型或2型糖尿病的女性被排除在外。获取了母亲的人口数据、孕期并发症,以及分娩和

Diabetes Care:FABP4预测1型糖尿病女性的子痫前期风险

子痫前期指怀孕前血压正常的孕妇在妊娠20周以后出现高血压、蛋白尿,又称为先兆子痫。是妊娠期高血压疾病的五种状况之一,为妊娠期特发疾病,可影响机体各器官系统。 脂肪酸结合蛋白4(FABP4)是胞内脂质结合蛋白超家族成员,在长链脂肪酸的摄取、转运及代谢调节中发挥重要作用,并涉及生物体的其他生命过程。 研究者对1型糖尿病女性患者进行了研究,探究FABP4和子痫前期风险之间的关系。 研究纳入了糖

JCEM:hCG+甲状腺功能,能否预测子痫前期风险?

在怀孕期间,对甲状腺激素的需求有所增加。妊娠时产生的人绒毛膜促性腺激素(HCG)是甲状腺功能的重要生理刺激。已有研究表明,母亲T4浓度位于正常高限时,子痫前期风险也会变高。 我们研究的假设为:根据HCG浓度可以区分高甲状腺功能的生理形式、高甲状腺功能的病理形式,以及这两种不同形式下的子痫前期风险也会是不同的。 这项以人群为基础的前瞻性队列研究,检测了5146名孕妇的TSH、FT4、hC

早孕时期hCG检测助于子痫前期风险预测

那些怀孕与甲状腺功能间牵扯不清的事众所周知,判断女性是否怀孕可以通过血hCG(人绒毛促性腺激素)检查来确定。hCG是在女性妊娠后自然升高的一种胎盘类激素,由于hCG分子跟TSH(促甲状腺激素)分子结构具有相似性,早在上世纪70年代就有实验证明hCG对甲状腺具有刺激作用。因此,在早孕时期由于hCG的快速增长,会导致血清甲状腺激素的升高,而TSH则会受到抑制。当然,滋养细胞疾病也会导致hCG分泌的大量

Int J Epidemiol:子痫前期孕妇怀女儿更容易早产?

子痫前期指怀孕前血压正常、妊娠20周以后出现高血压、蛋白尿;是妊娠期高血压疾病的五种状况之一,为妊娠期特发疾病,可影响机体各器官系统。目前其发病率约占全部妊娠的8%。 越来越多的证据表明,母亲、胎盘和胎儿之间存在性别特异性的相互作用,可能会导致孕期不同的适应机制。 我们进行了一项荟萃分析,探究胎儿性别和子痫前期之间的联系,此外重点关注了子痫前期患者分娩时的孕周。 本研究纳入了21

USPSTF呼吁:常规化孕期子痫前期筛查

美国预防服务工作组(USPSTF)对之前发布的声明草案进行了重申:呼吁孕期常规进行子痫前期的筛查。 关于血压测量对孕妇子痫前期筛查的益处,得到了机构的“适度”的肯定,推荐等级为B。 在对子痫前期检测方式进行评估时,USPSTF认为有足够的证据支持血压测量的准确度;此外,还有足够的证据表明,蛋白尿检测时,使用试纸测试尿蛋白的诊断准确率低。 在评估早期检测和治疗子痫前期的利弊时,有足

Baidu
map
Baidu
map
Baidu
map